An actively managed health care fund just posted a quarter worth talking about, which is rarer than it sounds. The Janus Henderson Global Life Sciences Fund returned 12.80% in Q2 2026, nearly double the 6.75% from its benchmark, the MSCI World Health Care Index.

Six percentage points of outperformance in one quarter is a real gap. I've spent plenty of words on this site explaining why most active managers don't beat their index over time, and that's still true, so when one posts a quarter like this the honest response is to nod and keep reading. One quarter tells you almost nothing about the next.

Health care has been an interesting case study lately. It's a defensive group by temperament, the sort of thing investors reach for when the broader market feels rich, and I wrote recently about what history says about owning defensive stocks before a crash. But it's also a sector where the gap between winners and casualties inside the same index can be enormous. Drug trials fail. Patents expire. One regulatory decision can move a stock by double digits in a day. That gap between the winners and the casualties is the argument for active management here, and also against it, depending on how the picking goes.

If you hold the fund, the quarterly commentary deserves a slow read. What you want to know is whether the outperformance came from durable judgments or one position that happened to catch a bid. A 12.80% quarter built on a single takeout bid or a single drug approval is a different animal than one built across a dozen holdings. Managers rarely advertise the difference. The holdings table usually tells you.

For everyone else, the takeaway is simpler. Own health care through a broad index fund and you captured that 6.75% without doing anything, and without paying an active fee for the privilege. If you're tempted to chase the fund that just beat its benchmark by six points, remember how these things tend to work. Last quarter's winner shows up in the marketing materials. Next quarter's results haven't been written yet. The funds that look brilliant today are usually the ones inflating the sector's appeal to new money.

I don't say that to dismiss the managers. Beating an index by that much in one quarter takes either genuine skill, favorable luck, or both, and sorting the two apart takes years of track record, not one statement. The Q2 number is a fact. Whether it repeats is a forecast.

If health care is a gap in your portfolio and you'd rather not referee individual drug trials, a broad health care ETF or even a total market fund gets you exposure with less drama. Patience and consistency still beat quarterly heroics over a full career. I've watched enough great quarters evaporate into mediocre decades to know that.

As always, this is my perspective, not professional financial advice. Do your own homework or talk to an advisor who knows your situation.